Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with child-pugh C liver cirrhosis

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 3039-3044

  Nishikawa, Hiroki ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Ohara, Yoshiaki ^a   Takeda, Haruhiko ^a   Sakamoto, Azusa ^a   Saito, Sumio ^a   Nishijima, Norihiro ^a   Nasu, Akihiro ^a   Komekado, Hideyuki ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Best supportive care; Child Pugh C; Hepatocellular carcinoma; Non transpalnt therapies; Overall survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER STAGING; CHILD PUGH SCORE; COMPARATIVE EFFECTIVENESS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; TRANSCATHETER ARTERIAL THERAPY; TUMOR VOLUME; AGED; BEST SUPPORTIVE CARE; CATHETER ABLATION; CHILD-PUGH C; COMPARATIVE STUDY; FOLLOW UP; LIVER TRANSPLANTATION; LIVER TUMOR; MORTALITY; NON-TRANSPALNT THERAPIES; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PROPENSITY SCORE; TREATMENT OUTCOME;

BEST SUPPORTIVE CARE; CHILD-PUGH C; HEPATOCELLULAR CARCINOMA; NON-TRANSPALNT THERAPIES; OVERALL SURVIVAL;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM STAGING; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROPENSITY SCORE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84906328258     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56(Suppl 1): S75-S87, 2012.
4. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
5. Page AJ, Cosgrove DC, Philosophe B and Pawlik TM: Hepatocellular Carcinoma: Diagnosis, Management, and Prognosis. Surg Oncol Clin N Am 23: 289-311, 2014.
6. Umemura T and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37(Suppl 2): S95-S100, 2007.
7. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 41: 903-909, 2012.
8. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249: 195-202, 2009.
9. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A and Lee C: Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197: W562-570, 2011.
10. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M and Makuuchi M: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469, 2006.
11. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B and Perrier A; OLT for HCC Consensus Group: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13: e11-22, 2012.
12. Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
13. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M and Makuuchi M; HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology JSH 2010 updated version. Dig Dis 29: 339-364, 2011.
14. Nishikawa H, Kimura T, Kita R and Osaki Y: Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. J Cancer 4: 635-643, 2013.
15. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
16. Strader DB, Wright T, Thomas DL and Seeff LB; American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171, 2004.
17. Nishikawa H, Osaki Y, Arimoto A, Kita R and Kimura T: Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma. Anticancer Res 33: 2211-2219, 2013.
18. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma. Anticancer Res 33: 1181-1188, 2013.
19. Liver Cancer Study Group of Japan: The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19: 98-129, 1989.
20. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281, 1998.
21. Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, Park SW, Yun SC, Gwon HC, Jeong MH, Jang Y, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS and Park SJ: Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 358: 1781-1792, 2008.
22. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y and Yamamoto K: Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 98: 1161-1165, 2008.
23. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kuzuya T, Nonogaki K and Shimizu J: Impact of tumor factors on the prognosis of patients with advanced cirrhosis Child-Pugh class C and hepatocellular carcinoma. J Gastroenterol Hepatol 20: 963-965, 2005.
24. Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y and Kumada H: High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 115: 571-580, 2009.